Physician profile
Michael A Lipsitt
NPI 1043206477
$2,275.78
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $136 · 2021: $250 · 2022: $68.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,699.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $157.46 | 2021-2022 | |
| United Therapeutics Corporation | $115.65 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.70 | 2019-2021 | |
| Amgen INC. | $51.70 | 2019-2021 | |
| Pfizer INC. | $40.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.02 | 2019 | |
| Bardy Diagnostics, INC. | $23.33 | 2021 | |
| Novo Nordisk INC | $21.89 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $19.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lipsitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.